News Archive - Navrogen : Navrogen

January 20, 2026

Navrogen Granted Composition of Matter and Use Patent to Humoral Immuno-Oncology (HIO) Factor Antagonist NAV-005 for the Treatment of Cancer

Navrogen, Inc. announced the issuance of U.S. Patent No. 12,516,096 covering NAV-005, a humoral immuno-oncology factor antagonist designed to overcome antibody suppression in multiple cancer types.

October 30, 2025

Navrogen Granted International Patents Covering Its Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate

Navrogen, Inc. announced the grant of European and Japanese patents covering its HIO platform technology and lead therapeutic NAV-001, an HIO-refractory ADC targeting mesothelin-expressing cancers.

September 29, 2025

Navrogen Granted Patent to Develop Antibodies and Next Gen Antibody Formats That Are Refractory to Immunosuppressive Humoral Immuno-Oncology (HIO) Factors

Navrogen, Inc. announced the issuance of U.S. Patent No. 12,416,642 covering its platform technology for detecting HIO-susceptible antibodies and engineering HIO-refractory cancer therapeutics.

September 8, 2025

Navrogen Awarded National Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology (HIO) Positive Cancers

Navrogen, Inc. announced an NCI grant award to advance development of antagonists targeting HIO-positive cancers, supporting therapies designed to overcome tumor-driven humoral immunosuppression.

May 5, 2025

Navrogen Announces Publication on the CA125-Refractory NAV-006 Antibody for the Treatment of Immunosuppressed Follicular Lymphoma

The article describes the negative impact that the Humoral Immuno-Oncology factor CA125 has on rituximab, obinutuzumab and tafasitamab, as well as T-cell engager antibodies, like mosunetuzumab and glofitamab, on...

March 26, 2025

Navrogen Announces Publication and Presentation at the American Association for Cancer Research (AACR) Annual Meeting of a Novel Antibody Engineering Platform

The article describes new criteria for monoclonal antibody and antibody-drug conjugate development to treat cancers over-expressing the humoral immunosuppressive oncology (HIO) factor ICAM-1